The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 701–800 of 979
Charismatic, Synchronous and Psychedelic Religious Experiences: A Personal Account
Macallan, B. C. (2022) · Religions · doi:10.3390/rel13040331 · Cited by 2
Barrett, F. S. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.07.005 · Cited by 2
Six groups of poisonous mushrooms: classified according to clinical symptoms
Yu, X. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v19i.2853 · Cited by 2
Near-death experiences: feasibility and advantages of the mechanistic explanation
Oleksowicz, M., & Gaitán, L. (2023) · Synthese · doi:10.1007/s11229-023-04307-y · Cited by 2
The Bad Seed: Mystical Experience and Time Travel in the Treatment of Psychopathy
Burton, N. (2023) · Psychoanalytic Dialogues · doi:10.1080/10481885.2023.2264338 · Cited by 2
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_94-1 · Cited by 2
Self-citationUso da psilocibina no tratamento de transtornos psiquiátricos: Revisão da literatura
Teixeira, G. B., Passos, A. C. D. B., Farias, B. V., Girão, A. B. C. F., Marçal, L. D. S., Albuquerque, K. O. D. S., & Ferreira, M. A. D. (2024) · Research Society and Development · doi:10.33448/rsd-v13i2.44971 · Cited by 2
Recent empirical work on religious experience: New directions
Skolits, W. (2024) · Philosophy Compass · doi:10.1111/phc3.12977 · Cited by 2
Shamanism and Psychedelic, Religious, Spiritual, and Mystical Experiences
Winkelman, M. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.37 · Cited by 2
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_94 · Cited by 2
Self-citationDrug-induced body disownership
Millière, R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0002 · Cited by 2
Turner, T., & Glue, P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0008 · Cited by 2
Furnell, M., & Gordon, W. V. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008802 · Cited by 2
Fernandes-Nascimento, M. H., Viana-Ferreira, K., & Negrão, A. B. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0031 · Cited by 2
Psychedelic Churches Need Philosophy of Religion
Steinhart, E. C. (2025) · Religions · doi:10.3390/rel16050641 · Cited by 2
Rebecchi, K. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00320 · Cited by 2
Overall, J. S. (2025) · Applied Psychology Research · doi:10.59400/apr3055 · Cited by 2
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
Salvia divinorum, Hallucinogens, and the Determination of Medical Utility
Griffin, O. H. (2013) · Springer eBooks · doi:10.1007/978-3-642-40957-8_8 · Cited by 2
Skeptheism: Is Knowledge of God’s Existence Possible?
Mizrahi, M. (2017) · European Journal for Philosophy of Religion · doi:10.24204/ejpr.v9i1.1864 · Cited by 2
The Scientific Study of Religion
Collicutt, J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.003 · Cited by 2
Coles, A. J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.002 · Cited by 2
Møter med det hellige: bruk av LSD,fleinsopp og andre psykedeliske stoffer
Pedersen, W. (2020) · Tidsskrift for samfunnsforskning · doi:10.18261/issn.1504-291x-2020-04-03 · Cited by 2
Forster, D. L. (2021) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12716 · Cited by 2
From personal to transpersonal? An evolutionary stance and ‘self’ as the centre of narrative gravity
Jackson, T. (2022) · Innovation The European Journal of Social Science Research · doi:10.1080/13511610.2022.2097057 · Cited by 2
Uso da psilocibina como ferramenta psicoterapêutica no tratamento da depressão: uma revisão
da Silva, J. R., da Costa, S. M., & da Silva, D. P. (2021) · Scire Salutis · doi:10.6008/cbpc2236-9600.2022.001.0035 · Cited by 2
Psychedelic Experiences and the Enactive Approach
Meling, D., & Scheidegger, M. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.9 · Cited by 2
Clarifying the relationship between social connectedness and connectedness to nature
Moreton, S. G. (2018) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
The chemical induction of synaesthesiaPreprint
Luke, D. P., Lungu, L., Friday, R., & Terhune, D. B. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/s6eh3 · Cited by 2
Measurement of the impact of orgasmic meditation on mystical experiencePreprint
Siegel, V., & Emmert‐Aronson, B. O. (2019) · MindRxiv (OSF Preprints) · doi:10.31231/osf.io/ug6vh · Cited by 2
Gwyther, M., & Aspell, J. E. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8ncj6 · Cited by 2
van Elk, M., & Yaden, D. B. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2236884 · Cited by 2
Irreversibility of Transformative Experience as a Criterion for Exceptionalism
Shevchenko, S., & Лаврентьева, С. В. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433452 · Cited by 2
Oliver, C. R., Luke, D., Evans, J., Aday, J. S., Johnson, M., Lake, S., Kruger, D. J., Kevin, F. B., & Lucas, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9304959/v1 · Cited by 2
Self-citationNeurologic Complications of Recreational Drugs
Josephson, S. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00034-5 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0009 · Cited by 1
Asimakopoulou, E., Theodosis‐Nobelos, P., & Triantis, C. (2024) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000139 · Cited by 1
Vogt, S. B., & Liechti, M. E. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.003 · Cited by 1
Glenn, D. L., Choi, S. H., & Zimmerman, R. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353251 · Cited by 1
The effect of psychedelics on associative learning: A systematic review
Caulfield, A., Li, L., Belessiotis‐Richards, C., Askari, F., Moura, R., Foldi, C. J., Young, A. H., & Mehta, M. A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106951 · Cited by 1
Bernal, A. M. O., Raison, C. L., Lancelotta, R., Timmermann, C., Sepeda, N. D., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577305 · Cited by 1
Dleštíková, T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105067 · Cited by 1
Perkins, D., Halman, A., Urokohara, A., Palumbo, J., Low, M., Ruffell, S., Coelho, N. L. G., Collins, L., Norman, A. F., & Sarris, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25767-x · Cited by 1
Kirlić, N., Atli, M., Mistry, S. J., Gold, M., & Goodwin, G. M. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002119 · Cited by 1
Theories of Psychedelic Drug Use
Alexander, R. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-01008-7_2 · Cited by 1
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., et al. (2026) · Religion Brain & Behavior · doi:10.1080/2153599x.2026.2635353 · Cited by 1
Self-citationRobinson, J., Wallace, N., Cassidy, E. K., Lake, S., & Lucas, P. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261444382 · Cited by 1
Belinger, L., Rieser, N. M., Engeli, E., Becciolini, L., Clamote, M., Pribiš, M., Saissi, F., Florineth, G. A., Hehl, N. L., Herdener, M., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112879 · Cited by 1
Psychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Erdmann, L., Breitenstein, B., Badanova, M., Telschow, L., Havenith, M. N., & Dziobek, I. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1777341 · Cited by 1
Armstrong, S. B., Levin, A. W., Sepeda, N. D., Shaub, H., Hunter, T., Douglas, A., Lancelotta, R., & Davis, A. K. (2026) · Communications Medicine · doi:10.1038/s43856-026-01767-4 · Cited by 1
The confidence reorientation account: psychedelics, self-model precision, and death anxiety
Zhang, F. (2026) · Philosophical Psychology · doi:10.1080/09515089.2026.2720478 · Cited by 1
Levy‐Cooperman, N., Sellers, E., Glue, P., Szeto, I., Brown, D., Jarecki-Smith, J., Tyler, W. J., & McDonnell, M. B. (2026) · Pharmaceuticals · doi:10.3390/ph19091496 · Cited by 1
Mixed toxin profiles in two new and one known species of Inocybe (Inocybaceae) from northern China
Liang, J.-Q., Chen, X., Liu, T.-Z., Zhang, Y., Sun, C., Li, Z., Zhong, J.-J., Li, H.-J., Fan, Y.-G., & Xu, F. (2026) · MycoKeys · doi:10.3897/mycokeys.141.203741 · Cited by 1
Phenomenology, Neurology, Psychiatry and Religious Commitment
Kidd, I. J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.006 · Cited by 1
MacLean, K. A., & Weber, G. (2013) · Religion Brain & Behavior · doi:10.1080/2153599x.2013.826726 · Cited by 1
My Experience as a Guide in the Johns Hopkins Psilocybin Research Project
Cosimano, M. P. (2014) · Cited by 1
PSILOCYBIN RESEARCH AT JOHNS HOPKINS: A 2014 REPORT
Jesse, R. L., & Griffi, R. R. (2014) · Cited by 1
Self-citationFreizeitgebrauch von LSD und Psilocybin-Pilzen
Prepeliczay, S. (2018) · Springer eBooks · doi:10.1007/978-3-658-22138-6_35 · Cited by 1
Parkinson’s Disease, Religious Belief and Spirituality
Barker, R. A., & Redfern, C. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.011 · Cited by 1
Methodological Hazards in the Neuroscientific Study of Religion
Judge, S. J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.004 · Cited by 1
Religion and Spirituality in Neuro-Rehabilitation
Collicutt, J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.017 · Cited by 1
Towards an Islamic Neuropsychiatry
Aggarwal, N. K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.009 · Cited by 1
Personhood and Religion in People with Dementia
Hughes, J. C. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.015 · Cited by 1
What Psilocybin Taught Me, One Year Later
Back, A. L. (2020) · Journal of Palliative Medicine · doi:10.1089/jpm.2020.0018 · Cited by 1
Penedos, S., Ramos, C. F., Miguel, M. J. L., Alves, M., Paulino, L., Azevedo, A., Magalhães, M., Moreno, L., Ribeiro, N. F. D. S., Fonseca, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.797 · Cited by 1
von Heyden, M., & Jungaberle, H. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_43 · Cited by 1
Snook, C. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_48 · Cited by 1
Plant and Fungal Hallucinogens as Toxic and Therapeutic Agents
Carlini, E. A., & Maia, L. O. (2015) · Springer eBooks · doi:10.1007/978-94-007-6728-7_6-1 · Cited by 1
Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin
Principe, A. (2022) · SURG Journal · doi:10.21083/surg.v14i1.6870 · Cited by 1
Psychedelic therapy for body dysmorphic disorder
Johnson, S., & Letheby, C. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00200 · Cited by 1
An, Y., Park, S.-Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.243 · Cited by 1
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
The DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate, B. C., Ermakova, A. O., Sloshower, J., Coelho, N. L. G., Palhano-Fontes, F., Antunes, H. F., de Assis, G. L., Cavnar, C., de Araújo, D. B., & Ribeiro, S. T. G. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00279 · Cited by 1
Pop, I. A., Gielens, E., & Kottmann, H. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00260 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0001 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0005 · Cited by 1
Substance‐Related and Addictive Disorders
Reichenberg, L. W., & Seligman, L. (2016) · Wiley eBooks · doi:10.1002/9781394259465.ch17 · Cited by 1
Development of the Japanese version of the Ego‐Dissolution Inventory (EDI)
Kusudo, K., Tani, H., Yonezawa, K., Nakajima, S., Nour, M. M., Carhart-Harris, R. L., & Uchida, H. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12419 · Cited by 1
Berghmann, C. (2024) · Etudes sur la mort/Études sur la mort · doi:10.3917/eslm.160.0169 · Cited by 1
Geschichte der Anwendung von Psychedelika
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2306-6120 · Cited by 1
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Kaiserman, A., Vanderijst, L., & Kornreich, C. (2024) · Psychiatria Danubina · doi:10.24869/psyd.2024.174 · Cited by 1
Charting the Experience of Children and Adolescents Affected by Emotional Neglect
Wojtyna, E., & Gierczyk, M. (2024) · Routledge eBooks · doi:10.4324/9781032621203 · Cited by 1
Pensar com corpo como pensar com espaço: aforismos imagéticos que afirmam um aprender por trilhas
Gondim, D. M., & Miarka, R. (2018) · Educação Matemática em Revista · Cited by 1
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential
Patil, S. A., & Hunsberger, H. C. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575429775260119043318 · Cited by 1
Therapeutic Induction of Altered States of Consciousness: Investigation of 1-20Hz Neurofeedback
Hargraves, H. (2017) · Scholarship@Western (Western University) · Cited by 1
Psychedelics and Mental Health
Milla, A. (2020) · NSUWorks (Nova Southeastern University) · Cited by 1
The metaphysical combat with death in the terminally ill and the psychedelic trail
Dutta, V. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.131326 · Cited by 1
Question-based Drug Development for psilocybin – Authors' reply
Carhart-Harris, R. L., & Nutt, D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30217-6 · Cited by 1
The Ethical Import of Entheogens
Falcon, J. (2017) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc001924 · Cited by 1
The Good Friday Experiment (Aka Marsh Chapel Experiment)
Kime, K. G. (2018) · Springer eBooks · doi:10.1007/978-3-642-27771-9_200209-1 · Cited by 1
Ibogaine as a Treatment For Alcohol Use Disorder: a Preclinical Investigation
Falkenhaug, S. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.24225145 · Cited by 1
Reproducing the Psychedelic Experience: “One of the 5 Most Meaningful Experiences in Life”?Preprint
Kajonius, P., & Sjöström, D. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/m6pqj · Cited by 1
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
van Elk, M. (2026) · Philosophical Psychology · doi:10.1080/09515089.2026.2662200 · Cited by 1
Jajcay, N., Vejmola, Č., Korčák, J., Tylš, F., Viktorinová, M., Viktorin, V., Bravermanová, A., Androvičová, R., Balíková, M., Horáček, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.731183 · Cited by 1
Flashback: The Return of Psychedelic Medicine
Maurer, L. (2012)
Towards a Meaningful Unfolding Universe (Part II)
King, C. C. (2013) · Scientific GOD Journal
The Psychedelic Renaissance: Horizons, the Fifth Annual Conference on Psychedelic Research
Cooper, M. (2016) · Einstein Journal of Biology and Medicine · doi:10.23861/ejbm20122823
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
